A groundbreaking study introduces stable inhalable mRNA treatment using nanoparticles that hold up during nebulization, ...

Most people don’t enjoy getting shots for treatments or vaccines. So, researchers are working to create more medicines, such ...

BioNTech, the German developer of a widely used mRNA vaccine for the coronavirus, agreed to pay US$800 million (HK$6.24 billion) to buy biotech company Biotheus, a developer of cancer drugs. In a ...

Most people don't enjoy getting shots for treatments or vaccines. So, researchers are working to create more medicines, such ...

On the other hand, Moderna Inc (NASDAQ: MRNA) posted a surprise profit and higher than expected revenue following the launch ...

There is currently no licensed vaccine for norovirus – commonly known as the winter vomiting bug – but are scientists getting ...

SyVento says bringing the FlexFactory to Poland makes new therapies available to patients in an efficient and high-quality way.

Expects to complete enrollment of the 400-participant sentinel cohort for the COVID-19 Phase 2b study in November 2024 Solid financial position enables Vaxart to attain multiple regulatory and ...

Reactogenicity is comparable for simultaneous and sequential administration of mRNA COVID-19 and influenza vaccines.

BioNTech plans to further investigate the drug’s potential in combination with mRNA vaccines, targeted therapies and ...

The duo worked in the Kibo laboratory module's Life Science Glovebox, processing and imaging messenger RNA (mRNA) samples.

BioNTech said that it is acquiring the Chinese drugmaker Biotheus for $800 million to bolster its cancer strategy. The two ...